


What to Buy, Sell and Hold

Cadila Healthcare



■ **CLSA** has upgraded **Cadila Healthcare** to 'buy' from 'underperform' and raised target price to ₹450 from ₹440. The brokerage said it is upgrading the stock due to attractive valuations. A strong US pipeline despite a high base, and improving India and EM outlook led by biosimilar and vaccines launches are the key potential earnings drivers for Cadila, said CLSA. Shares of Cadila Healthcare ended down 1.74% at ₹369.95 on Friday.

■ **Sharekhan** has upgraded **Hindustan Unilever** to 'buy' from 'hold' with a target price of ₹1,440. The recent correction in the stock price provides a good opportunity to investors, said Sharekhan. Hindustan Unilever is expected to post double-digit earnings growth of 19% over the next three years on account of expected improvement in the demand environment, the brokerage said. Shares of Hindustan Unilever ended down 0.95% at ₹1,299.75 on Friday.

■ **IIFL** has a 'buy' rating on **YES Bank** with a target price of ₹400. The recent underperformance in Yes Bank's stock has been triggered by concerns of worsening asset quality amid tightening regulations, said IIFL. The brokerage believes YES Bank has robust resolution processes and will be able to recover the bulk of its stressed assets. Valuations are attractive, said IIFL. Shares of YES Bank ended down 3.87% at ₹286.70 on Friday.

■ **Reliance Securities** has a 'buy' rating on **JK Lakshmi Cement** with a target price of ₹550. Recovery in realization of Eastern markets in the last two months along with resumption of petcoke usage in Northern plants is likely to aid the company's profitability in current quarter, the brokerage said. Shares of JK Lakshmi Cement ended up 1.52% at ₹449.8 on Friday.